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This overview highlights some recent advances in the epidemiology, diagnosis, risk stratiﬁcation
and treatment of acute coronary syndromes. The sheer volume of new studies reﬂects the robust
state of global cardiovascular research but the focus here is on the ﬁndings that are of most
interest to the practising cardiologist.
Incidence and mortality rates for myocardial infarction are in decline, probably owing to a combi-
nation of lifestyle changes, particularly smoking cessation, and improved pharmacological and
interventional treatment. Troponins remain central for diagnosis and new high-sensitivity assays
are further lowering detection thresholds and improving outcomes. The incremental diagnostic
value of other circulating biomarkers remains unclear and for risk stratiﬁcation simple clinical algo-
rithms such as the GRACE score have proved more useful.
Primary PCI with minimal treatment delay is the most effective reperfusion strategy in ST elevation
myocardial infarction (STEMI). Radial access is associated with less bleeding than with the femoral
approach, but outcomes appear similar. Manual thrombectomy limits distal embolisation and
infarct size while drug-eluting stents reduce the need for further revascularisation procedures.ation initiative involving all
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40 C. Knight, A.D. TimmisNon-culprit disease is best dealt with electively as a staged procedure after primary PCI has
been completed. The development of antithrombotic and antiplatelet regimens for primary
PCI continues to evolve, with new indications for fondaparinux and bivalirudin as well as small-mol-
ecule glycoprotein (GP) IIb/IIIa inhibitors. If timely primary PCI is unavailable, ﬁbrinolytic treat-
ment remains an option but a strategy of early angiographic assessment is recommended for all
patients.
Non-ST segment elevation myocardial infarction (NSTEMI) is now the dominant phenotype and
outcomes after the acute phase are signiﬁcantly worse than for STEMI. Many patients with
NSTEMI remain undertreated and there is a large body of recent work seeking to deﬁne the
most effective antithrombotic and antiplatelet regimens for this group of patients. The beneﬁts
of early invasive treatment for most patients are not in dispute but optimal timing remains unre-
solved.
Cardiac rehabilitation is recommended for all patients with acute myocardial infarction but take-up
rates are disappointing. Home-based programmes are effective and may be more acceptable for
many patients. Evidence for the beneﬁts of lifestyle modiﬁcation and pharmacotherapy for second-
ary prevention continues to accumulate but the argument for omega-3 fatty acid supplements is now
hard to sustain following recent negative trials. Implantable cardioverter-deﬁbrillators for patients
with severe myocardial infarction protect against sudden death but for primary prevention should
be based on left ventricular ejection fraction measurements late (around 40 days) after presentation,
earlier deployment showing no mortality beneﬁt.
ª 2012 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.Contents
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Temporal trends for the global coronary epidemic vary by re-
gion but in most developed countries mortality is in decline.1
Lifestyle adjustments have contributed to this decline––most
recently, the implementation of comprehensive smoke-free leg-
islation in many countries has already caused signiﬁcant reduc-
tions in acute coronary events.2 Smoking, a potent
thrombogenic stimulus, is a major determinant of STEMI3
and a recent analysis from Kaiser Permanente in California––
where smoke-free legislation is strictly enforced––showed a
62% decline in STEMI between 1999 and 2008 while NSTEMI
increased by 30%.4 Overall, there was a 24% reduction in hos-
pitalisations for acute coronary syndromes despite lowering of
diagnostic thresholds by sensitive troponin biomarkers.5 This
was accompanied by improvement in the age- and sex-adjusted
30-day mortality from 10.5% in 1999 to 7.8% in 2008. Increas-
ing rates of interventional management no doubt contributed
to the improved outcomes but parallel increases in plaque-sta-
bilising treatment with high-dose statins must also have played
a role6 because vulnerable thin-cap ﬁbroatheromas, often re-
mote from the infarct-related artery and unrelated to stenosis
severity, are the sites at which recurrent plaque events usually
occur.7,82. Diagnosis
Diagnostic deﬁnitions of acute coronary syndromes are inter-
nationally agreed based on troponin release and symptomatic,
electrocardiographic, or functional criteria.9
2.1. Troponins
Demonstration of a changing troponin concentration in the
ﬁrst 24 h with at least one value above the decision limit is cen-
tral to the diagnosis of acute myocardial infarction. Now avail-
able are high-sensitivity troponin assays permitting signiﬁcant
reductions in the threshold for detection. An early study eval-
uated four high-sensitivity assays in 718 patients with sus-
pected acute coronary syndrome, 17% of whom had acute
myocardial infarction. Diagnostic performance was excellent,
the area under the receiver operator curves ranging from
0.95 to 0.96 compared with 0.90 for the standard assay.10
The implications for cardiac outcomes and clinical manage-
ment were assessed in a more recent study in which
high-sensitivity troponin I was measured in 1038 patients with
suspected acute coronary syndrome.11 Values below the previ-
ous limit of detection (0.20 ng/ml)––conventionally considered
‘normal’––showed graded association with death or non-fatal
myocardial infarction, with rates of 7% and 39% for troponin
concentrations of <0.05 ng/ml and 0.05–0.19 ng/ml, respec-
tively. When the investigators lowered the diagnostic threshold
to 0.05 ng/ml in further 1054 patients, communicating tropo-
nin values to clinicians, the risk of death and recurrent myo-
cardial infarction in patients with troponin concentrations
0.05–0.19 ng/ml was reduced from 39% to 12%. The investiga-
tors concluded that lowering the diagnostic threshold by clin-
ical application of high-sensitivity troponin assay has the
potential to identify many high-risk individuals with suspected
acute coronary syndrome and produce major improvements in
their prognosis.2.2. Other diagnostic biomarkers
Studies evaluating new biomarkers for the early diagnosis of
myocardial infarction have been the subject of a recent system-
atic review.12 The quality of these studies has often been poor
with only 16% providing any information about incremental
value compared with other diagnostic data. Myoglobin, for
example, appears to be useful to rule out myocardial infarction
in the ﬁrst 6 h but evidence that it adds value to clinical symp-
toms, ECG and troponin testing is limited. Of the new
diagnostic biomarkers, ischaemia-modiﬁed albumin and
heart-type fatty acid-binding protein (H-FABP) showed initial
promise, but already a meta-analysis has concluded that H-
FABP does not fulﬁl the requirements needed for early diagno-
sis when used as a stand-alone test and called for evidence that
it adds to clinical evaluation and other diagnostic tests.13
2.3. Point-of-care diagnosis with a panel of biomarkers
Whether biomarker panels have a speciﬁc role for the early
diagnosis of myocardial infarction in the emergency room
has been evaluated in two recent studies, both using a point-
of-care panel of troponin I, creatine kinase-MB (CK-MB)
and myoglobin. RATPAC recruited 2243 patients with sus-
pected myocardial infarction and randomised them to stan-
dard care or panel evaluation on admission to the emergency
room and 90 min later.14 Point-of-care panel evaluation was
associated with a 32% rate of ‘successful’ (no re-attendance
with major coronary events) discharge from the emergency
room, compared with 13% for standard care; hospital bed
use was unaffected. However, a substudy to examine the diag-
nostic efﬁciency of the individual cardiac markers and their
accuracy for the ﬁnal diagnosis of acute myocardial infarction
showed that point-of-care myoglobin and CK-MB did not
provide further diagnostic information over that provided by
troponin I for early diagnosis or exclusion of myocardial
infarction.15 ASPECT was an observational study of 3582
patients in which an accelerated diagnostic panel (ADP) of
TIMI score, coupled with the point-of-care panel of biomark-
ers and ECG ﬁndings, identiﬁed 352 as low risk.16 Only three
of these patients went onto experience a major adverse cardiac
event, making the ADP a highly sensitive rule-out for myocar-
dial infarction in low-risk patients, as reﬂected by a negative
predictive value of 99.1%. However, there was no control
group in ASPECT, nor an analysis of the incremental value of-
fered by individual components of the biomarker panel. Based
on the RATPAC subgroup analysis, therefore, it seems clear
that troponin remains the most useful biomarker for the diag-
nosis of myocardial infarction in the emergency room and cur-
rent evidence is insufﬁcient to advocate biomarker panels for
this purpose.
2.4. Electrocardiogram
Guideline recommendations are for urgent reperfusion therapy
according to STEMI pathways in patients with suspected myo-
cardial infarction presenting with left bundle branch block
(LBBB). However, a retrospective analysis of 892 patients in
a Mayo Clinic STEMI registry, found that of the 36 who pre-
sented with new LBBB, only 12 (33%) had a ﬁnal diagnosis of
acute myocardial infarction.17 These data show that LBBB is
of limited diagnostic utility in suspected myocardial infarction
42 C. Knight, A.D. Timmisand provides a case for new diagnostic strategies in this high-
risk group. Also at high risk are patients with acute myocardial
infarction caused by proximal left anterior descending coro-
nary artery (LAD) occlusion. A report that this may be asso-
ciated with a distinct ECG pattern has now been conﬁrmed
in a series of 35 patients who underwent primary PCI of the
LAD, all of whom showed ST-segment depression at the J-
point with up-sloping ST segments and tall, symmetrical
T-waves in the precordial leads of the 12-lead ECG.18,19 The
authors recommend that this ECG pattern in patients present-
ing with suspected myocardial infarction should prompt triage
for immediate reperfusion therapy.2.5. Imaging
Echocardiography provides the most readily available imaging
modality for the acute phase diagnosis of myocardial infarc-
tion by identifying new left ventricular regional wall motion
abnormality. A new diagnostic application for identifying
those patients with NSTEMI who have complete coronary
occlusions was recently described.20 In such patients, circum-
ferential strain measured within 1 h of admission was indepen-
dently diagnostic, values P10% showing 90% sensitivity and
88% sensitivity for angiographic coronary occlusion. The
authors suggest that strain measurements in the acute phase
of NSTEMI might be used for triaging patients for immediate
reperfusion therapy.3. Risk stratiﬁcation
The risk of death and other ischaemic events in patients with
acute coronary syndromes varies considerably across diagnos-
tic phenotypes. Objective criteria to quantify risk are now
increasingly used to guide treatment and determine prognosis.
3.1. Clinical factors
Clinical factors are used intuitively by clinicians. They recog-
nise that risk increases with age and shows important gender
differences––young women with STEMI, for example, having
a 15–20% higher mortality risk than men.21 ECG criteria22
and routine biochemistry are also used for risk stratiﬁcation,
outcomes worsening with admission hyperglycaemia and also
it seems with admission hypoglycaemia.23,24 Despite clinicians’
reliance on clinical assessments of risk it is now clear that they
often get it wrong and a recent study has shown little associa-
tion with objective measures of risk using validated risk
scores.25
3.2. Diagnostic biomarkers
Increasing troponin release in NSTEMI is associated with a
proportionate increase in the risk of lethal arrhythmias, car-
diogenic shock, new heart failure and death.26 C-reactive pro-
tein, the most widely studied prognostic biomarker, is also
moderately predictive of adverse outcomes in acute coronary
syndromes, a recent meta-analysis reporting a pooled RR of
2.18 (1.77–2.68) for the top (>10 mg/l) compared with the
bottom (63 mg/l) category of values,27 Generally speaking,
however, individual biomarkers have yet to ﬁnd a useful clin-
ical role––a recent 5-year follow-up of patients with NSTEMIincluded in FRISC II reporting that none of N-terminal pro-
brain natriuretic peptide (NT-proBNP), C-reactive protein,
cardiac troponin I and estimated glomerular ﬁltration rate pro-
vided incremental prognostic value to established risk indica-
tors, except NT-proBNP for 6-week outcomes.28 Combining
multiple biomarkers may improve predictive power for adverse
outcomes but conﬁrmation of incremental value over estab-
lished risk scores is still awaited.29
3.3. Risk scores
Validated risk scores based on a range of readily available
factors provide the most effective means of risk stratifying
patients with acute coronary syndromes. The GRACE score is
widely used and in a comparative validation study involving
100,686 cases of acute coronary syndromes its discriminative
performance in predicting mortality compared favourably with
a range of other risk models including PURSUIT, GUSTO-1,
GRACE, SRI and EMMACE.30 The GRACE score appears
to have lost none of its clinical value with the availability of
high-sensitivity cardiac troponin assays. In an international co-
hort of 370 patients with acute coronary syndromes, the area un-
der the curve of the GRACE score was 0.87 and 0.88 for in-
hospital and 1-year mortality, and addition of high-sensitivity
cardiac troponin produced no improvement in the mortality
prediction.314. Primary percutaneous coronary intervention
The MINAP public report for England and Wales records that
70% of all patients with STEMI received reperfusion therapy
in 2010/2011, of whom 81% received primary PCI.32 The drive
towards primary PCI, based on the evidence of a sustained
mortality beneﬁt compared with ﬁbrinolysis,33 has been under-
pinned by the establishment of regional networks that have
deﬁned local standards of care and provided infrastructure
for stafﬁng heart attack centres.34,35
Timely treatment is essential to maximise prognostic bene-
ﬁt,36,37 and important as it is to achieve door-to-balloon times
within 90 min, other intrinsic delays within the healthcare pro-
cess also need consideration. Thus, a Danish registry analysis
of 6209 patients with STEMI found that ‘system delay’ (time
from ﬁrst contact with the healthcare system to the initiation
of reperfusion therapy)––as well as door-to-balloon time––
was a key modiﬁable risk factor, with an HR for mortality dur-
ing the next 3.4 years of 1.22 (95% CI 1.15–1.29; p< 0.001)
per 1 h increase in system delay.38 The ﬁndings emphasise
the importance of minimising transfer times from non-PCI
hospitals and introducing policies of prehospital diagnosis to
permit direct delivery of patients with STEMI to interventional
centres. Also important are strategies to reduce the time it
takes people with chest pain to call the emergency services.
Women take signiﬁcantly longer than men but, despite a US
campaign to increase women’s awareness of their risk of heart
disease, a recent study found that it had no effect on the gender
gap or the time it took women to call the emergency services.39
4.1. Vascular access
Primary PCI by radial rather than femoral access is the pre-
ferred approach for an increasing number of operators.40 Its
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cations––the randomised RIVAL trial of radial versus femoral
access in 7021 patients with acute coronary syndromes report-
ing a trend towards lower bleeding rates at 30 days (0.7% vs
0.9%), associated with signiﬁcantly lower rates of access-site
complications, including large haematomas and pseudoaneu-
rysms.41 Findings were similar in a recent observational study
of 1051 primary PCI cases with vascular complication rates of
0% and 1.9% for radial versus femoral access.42 However,
RIVAL found no outcome advantage for radial access, and
femoral access is still preferred by many operators43 because
access is more predictable and procedure times may be shorter
than with the radial approach.44,45
4.2. Stenting
Concerns about stent thrombosis led to recommendations for
bare metal stents in primary PCI but randomised trials have
now conﬁrmed important advantages for drug-eluting stents.
The HORIZONS-AMI 3-year results showed lower rates of
target lesion revascularisation for the 2257 patients random-
ised to paclitaxel-eluting stents than for the 749 patients ran-
domised to bare metal stents (9.4% vs 15.1%).46 There was
no difference by stent type in the rates of death, reinfarction,
stroke or stent thrombosis. Drug-eluting stents are, therefore,
preferred in primary PCI but they commit the patient to a full
12 months of dual antiplatelet treatment and if urgent surgery
is planned or there is a high risk of bleeding for other reasons
bare metal stents should be chosen.
4.3. Culprit lesion versus multivessel PCI
The main purpose of primary PCI is to achieve reperfusion of
jeopardised myocardium by reopening the culprit coronary
artery. Whether it is safe or desirable to treat disease within
non-culprit vessels during the primary PCI procedure or as a
staged procedure afterwards has been the subject of recent
investigation. A small randomised trial of 214 patients with
multivessel disease found that adverse event rates during a
mean follow-up of 2.5 years were higher with culprit PCI than
with multivessel PCI whether performed during the primary
PCI procedure or, better, as a staged procedure afterwards.47
This trial has now been included in a meta-analysis of four
prospective and 14 retrospective studies involving 40,280 pa-
tients, which came to a similar conclusion in showing that
staged PCI was associated with lower mortality compared with
culprit PCI.48 However, multivessel PCI during the primary
procedure was associated with the highest mortality. A post
hoc analysis of the HORIZONS-AMI trial also found that
staged PCI was associated with lower 1-year mortality com-
pared with culprit PCI (2.3% vs 9.2%).49 These data are con-
sistent in showing that multivessel disease is best dealt with
electively as a staged procedure after the primary PCI proce-
dure has been completed.
4.4. Thrombectomy
Thrombotic coronary occlusion is the pathological event trig-
gering STEMI and provides the logic for adjunctive thrombec-
tomy during primary PCI. A variety of devices have been
developed for this purpose but the simplest, manual thrombus
aspiration, has emerged as the best, with evidence of betterreperfusion during the acute phase of STEMI translating into
a survival advantage at 1 year compared with conventional pri-
mary PCI.50,51 MRI has conﬁrmed that thrombus aspiration re-
duces microvascular obstruction during primary PCI and limits
infarct size at 3 months.52 Amore recent analysis of pooled indi-
vidual patient data from three randomised trials found that the
trend for worsening myocardial reperfusion with time from
admission to primary PCI was effectively abolished by throm-
bus aspiration, suggesting particular beneﬁts in the event of pro-
cedural delay.53 More complex thrombectomy devices are not
recommended for use in STEMI. Thus assessments of infarct
size reduction in two trials––JETSTENT comparing Angiojet
rheolytic thrombectomy with primary direct stenting and PRE-
PARE comparing simultaneous proximal embolic protection
andmanual thrombus aspiration withmanual thrombus aspira-
tion––showed no signiﬁcant beneﬁt of these device strate-
gies.54,55 Consistent with this is a meta-analysis of
thrombectomy trials showing that the mortality beneﬁt for pa-
tients randomised to thrombus extraction is conﬁned to patients
treated with manual thrombectomy.56
4.5. Antiplatelet strategies
Current recommendations are for loading doses of aspirin and
clopidogrel immediately before primary PCI followed by
maintenance treatment. Adjunctive treatment with GPIIb/IIIa
receptor blockers provides more intensive platelet inhibition in
the acute phase. The main purpose of treatment is to enhance
thrombus resolution and to prevent recurrent thrombotic
events, particularly stent thrombosis in the 9–12 months it
takes for drug-eluting struts to endothelialise (1–3 months
for bare metal struts). Newer, drugs that block the ADP
P2Y12 receptor more potently than clopidogrel are now avail-
able57 and have been evaluated in combination with aspirin in
patients undergoing primary PCI. In the TRITON-TIMI 38
trial of dual antiplatelet treatment, prasugrel reduced the pri-
mary outcome of cardiovascular death, non-fatal myocardial
infarction and non-fatal stroke compared with clopidogrel
(6.5% vs 9.5%), but this was associated with a signiﬁcantly
greater risk of major bleeding, including fatal bleeding, raising
important safety concerns.58 Ticagrelor has also been evalu-
ated against clopidogrel in a substudy of the PLATO trial
and like prasugrel it proved more effective in reducing the
primary outcome of cardiovascular death, myocardial infarc-
tion or stroke, although the absolute difference was small
(9.0% vs 10.7%).59 Strikingly, however, there appeared to be
enhanced bleeding, and ticagrelor now has a guideline recom-
mendation for use in primary PCI, although its ﬁnal place in
the therapeutic arsenal must await cost-effectiveness and
long-term safety studies.
Abciximab, given intravenously, has been themost widely used
GPIIb/IIIa receptor blocker in patients with STEMI undergoing
primary PCI. Beneﬁts appear to be inversely related to inﬂamma-
tory burden60 and may be enhanced by intracoronary administra-
tion, a recent meta-analysis reporting improved clinical outcomes
by this route.61 However, abciximab is expensive and there are
now studies conﬁrming non-inferiority of ‘small-molecule’
GPIIb/IIIa receptor blockers. Thus, investigators using the
Swedish Coronary Angiography and Angioplasty Registry com-
pared 2355 primary PCI patients who received eptiﬁbatide with
9124 who received abciximab and found similar rates of death
or myocardial infarction during 1-year follow-up (15.0% vs
44 C. Knight, A.D. Timmis15.7%).62 In a smaller study, 427 patients randomised either to
eptiﬁbatide or abciximab showed comparable rates of complete
ST-segment resolution 60 min after primary PCI (62.6% vs
56.3%)with no signiﬁcant differences between cardiovascular out-
comes.63 In the On-TIME 2 trial, another small molecule com-
pound, tiroﬁban, in combination with aspirin and clopidogrel,
provided more effective platelet inhibition than aspirin and clopi-
dogrel alone in patients undergoing primary PCI. The degree of
platelet inhibition showed signiﬁcant relationship with major ad-
verse cardiac events, including stent thrombosis.64 These ﬁndings
have yet to penetrate international guidelines but many centres
are now switching from abciximab to small-molecule compounds
to reduce pharmacological costs.
4.6. Other antithrombotic drugs
4.6.1. Fondaparinux
Intravenous heparin during primary PCI further enhances
thrombus resolution during primary PCI but ongoing treat-
ment with low molecular weight heparin has now given way
to fondaparinux, a synthetic factor Xa inhibitor. A recent indi-
vidual patient-level combined analysis of 26,512 patients from
the OASIS 5 and 6 trials who were randomised to fondapari-
nux 2.5 mg daily or a heparin-based strategy has resolved
uncertainty about the clinical value of fondaparinux in pa-
tients undergoing primary PCI by showing a better net clinical
composite of death, myocardial infarction, stroke, or major
bleeding (10.8% vs 9.4%; HR= 0.87; p= 0.008) in the subset
of 19,085 patients treated invasively.65 A similar beneﬁt was
found in patients treated conservatively. Fondaparinux is
now widely used in preference to heparin in acute coronary
syndromes.
4.6.2. Bivalirudin
Bivalirudin is a direct thrombin inhibitor that showed superior-
ity to a combined regimen of heparin plus a GPIIb/IIIa inhibi-
tor in HORIZONS-AMI, largely owing to a lower rate of major
bleeding (4.9% vs 8.3%).66 All-cause mortality at 30 days was
also lower in the bivalirudin group, with persistent beneﬁt after
3 years (5.9% vs 7.7%), assuring a guideline recommendation
for bivalirudin in primary PCI.46 It should be noted, however,
that femoral artery access was used in 94.1% of the HORI-
ZONS-AMI population and whether the reduction in bleeding
with bivalirudin applies equally to centres where radial access is
the preferred approach is not known.
5. Fibrinolytic treatment
Evidence that ﬁbrinolysis is less effective than primary PCI in
the emergency management of STEMI, has now been rein-
forced by the evidence of reduced cost-effectiveness,67 yet a sig-
niﬁcant minority of patients in England and Wales continues
to be treated with it.32 This may be justiﬁed if ﬁbrinolysis
can be delivered within 30 min after presentation when
primary PCI is not immediately available, because treatment
delays by either modality are associated with substantial in-
creases in mortality.36 This has provided justiﬁcation for the
programmes of pre-hospital thrombolysis, particularly in the
rural regions where transport times are prolonged, but enthu-
siasm for this approach may now be diminished by evidence
from the MINAP registry showing higher rates of reinfarctioncompared with in-hospital thrombolytic treatment for patients
with STEMI.68 The difference in reinfarction rates was only
signiﬁcant for tenecteplase (9.6% vs 6.4%), not reteplase,
and was particularly marked when transport times exceeded
30 min. It was attributed to differences in the use of adjunctive
antithrombotic treatment in the two treatment environments.
Interestingly, bleeding complications were more common in
the hospital environment where adjunctive antithrombotic
treatment was more aggressive, consistent with recent data
from RIKS-HIA showing that major bleeding complications
among patients receiving ﬁbrinolytic treatment continued to
increase from 2001 to 2006 as antithrombotic treatments be-
came more effective.69 The availability of potent ADP
P2Y12 receptor blockers has raised further concerns about
bleeding complications, and it was gratifying, therefore, that
the PLATO trial substudy conﬁrmed that event rates could
be reduced with ticagrelor compared with clopidogrel without
an increase in bleeding risk.70,71
The role of invasive treatment after ﬁbrinolytic treatment in
STEMI has been clariﬁed in two recent meta-analyses of small
and medium-size trials comparing strategies of routine early
angiography for all patients with deferred or ischaemia-guided
angiography.72,73 Both meta-analyses reported that routine
early angiography was associated with reductions in the rates
of recurrent myocardial infarction and death and this strategy
is now recommended in international guidelines.
6. Non-ST-segment elevation myocardial infarction
NSTEMI has become the dominant mode of presentation for
patients with acute myocardial infarction and in the recent anal-
ysis from Kaiser Permanente accounted for 66.9% of cases.4
There has been a perception that NSTEMI is relatively benign
despite evidence that prognosis after 2 months becomes
substantially worse than with STEMI.21,74 This may explain
the tendency of doctors to under-treat NSTEMI based on a
mismatch between perceived and actual risk that distorts man-
agement decisions, perpetuating the ‘treatment-risk paradox’.25
Thus, despite a worse prognosis, patients with NSTEMI are less
likely than patients with STEMI to receive optimal secondary
prevention treatment.75 Moreover, in a study of 13,489 NSTE-
MI admissions recorded in the MINAP registry, invasive man-
agement was associated with better outcomes but was applied
inequitably, with lower rates in high-risk groups, including old-
er patients, women and those with cardiac comorbidities.76
6.1. Emergency management
Dual antiplatelet treatment with aspirin and clopidogrel is cen-
tral to the management of NSTEMI.77 The role of newer more
potent ADP P2Y12 receptor blockers remains undetermined,
although ticagrelor looks promising, based on its ability to re-
duce ischaemic events compared with clopidogrel in NSTEMI
as well as STEMI, without increasing the risk of bleeding.78
Simultaneous treatment with fondaparinux is now recom-
mended in preference to enoxaparin, based on the ﬁndings in
OASIS 5 which compared these agents in 20,078 patients with
acute coronary syndromes.79 Patients randomised to fonda-
parinux showed a 50% reduction in major bleeding compared
with enoxaparin, with no difference in the incidence of ischae-
mic events. The reduction in bleeding risk was comparable
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prescribed80 and cost-effectiveness has now been conﬁrmed.81
Indications for bivalirudin in NSTEMI have been harder to
deﬁne and although it has a licence for use in combination with
aspirin and clopidogrel, this is based principally on its safety
proﬁle (lower bleeding risk), its efﬁcacy for reducing ischaemic
events being no greater than either heparin plus GPIIb/IIIa
receptor blocker or bivalirudin plus GPIIb/IIIa receptor
blockers.82
The majority of patients with NSTEMI beneﬁt from inter-
ventional management,83 but recent data suggest this could be
delayed for at least 24 h unless continuing clinical instability
unresponsive to GPIIb/IIIa receptor blockers calls for earlier
action. Thus, in a randomised comparison of immediate versus
deferred PCI in 251 patients, the incidence at 30 days of the pri-
mary end point, a composite of death, non-fatal myocardial
infarction or unplanned revascularisation, was signiﬁcantly
higher in the group receiving immediate PCI (60% vs 39%).84
The difference persisted at 6 months’ follow-up. Delaying inter-
vention beyond 96 h is unlikely to be helpful, yet registry data
show that this is common, particularly in high-risk patients
who have most to gain from revascularisation.85 The evidence
for timely revascularisation is largely based on PCI data but a
small proportion of patients requires coronary artery bypass
grafting (CABG). An analysis of US registry data showed that
the timing of CABG has no palpable effect on outcomes, the
composite of death, myocardial infarction, congestive heart
failure, or cardiogenic shock being similar (12.6% vs 12.4%)
whether CABG is done within 48 h of admission or later.86 In
general, therefore, early surgery is recommended to limit hospi-
tal stay and reduce resource use.7. Secondary prevention
7.1. Cardiac rehabilitation
The beneﬁt of cardiac rehabilitation among 30,161 Medicare
beneﬁciaries, 20.5% of whom had recent myocardial infarction,
was conﬁrmed by a strong dose–response relationship between
the number of rehabilitation sessions attended and long-term
rates of death and myocardial infarction.87 Yet a contemporary
report of cardiac rehabilitation in the UK found that only 26%
of eligible patients with myocardial infarction are recruited,
with adherence rates of 65–85%.88 Reasons for the poor uptake
are complex but include the fact that many patients do not want
to participate in centre-based group programmes. A systematic
review has now reported that home-based programmes are
equally effective in improving clinical and health-related qual-
ity-of-life outcomes and are more acceptable to many pa-
tients.89 Healthcare costs are similar, supporting the further
provision of home-based cardiac rehabilitation such as that de-
scribed by investigators in Birmingham.90 The recent demon-
stration of improved myocardial blood ﬂow plus reductions in
circulating angiogenic cytokines in patients undergoing cardiac
rehabilitation provides some reassurance that clinical improve-
ment is physiologically based.91
7.2. Lifestyle modiﬁcation
An important component of cardiac rehabilitation is lifestyle
adjustment to help protect against further coronary events.Top of the list is smoking cessation. A recent study of 1581 pa-
tients followed up for 13 years showed that the adjusted HR for
all-cause mortality was lower by 43% in lifelong non-smokers
and by 43% in patients who quit after myocardial infarction.92
A new ﬁnding was that among persistent smokers, each reduc-
tion of ﬁve cigarettes smoked per day reduced the risk of death
by 18%, providing some comfort for those patients for whom
complete abstinence proves impossible. Even among patients
who mange to quit, there remains the hazard of second-hand
smoke exposure, as reﬂected by data from Scotland showing
that adjusted all-cause and cardiovascular mortality among
never-smoking survivors of myocardial infarction increases
according to smoke exposure measured by serum cotinine con-
centration.93 The message is clear that protection against recur-
rent events in survivors of myocardial infarction requires
smoking cessation by the patient and also by those with whom
the patient makes contact, particularly family members.
Together with smoking cessation, advice about exercise and
diet delivered in formal programmes can have a salutary effect
on modiﬁable risk proﬁles, including serum cholesterol, blood
pressure and body mass index.94 Dietary recommendations
usually include x-3 fatty acid supplements95 but this has now
been questioned by the ﬁndings of two studies. In the ﬁrst,
4837 patients with previous myocardial infarction were ran-
domised to margarines containing marine n-3 fatty acids and
plant-derived a-linolenic acid in a 2 · 2 factorial design.96
The rate of adverse cardiovascular events did not differ signif-
icantly among the study groups. In the second study, highly
puriﬁed x-3 fatty acids were randomly allocated to 3851 pa-
tients with acute myocardial infarction followed up for
12 months.97 There were no signiﬁcant differences in the rates
of sudden cardiac death (1.5% vs 1.5%), total mortality (4.6%
vs 3.7%), or major adverse cerebrovascular and cardiovascular
events (10.4% vs 8.8%) between treatment and placebo
groups. The results of these two trials make recommendations
for secondary prevention with x-3 fatty acid supplements after
myocardial infarction difﬁcult to sustain.
7.3. Pharmacotherapy
The importance of optimal secondary prevention after myo-
cardial infarction was emphasised in a modelling study, in
which greater absolute gains in survival were achieved by opti-
mising secondary prevention treatments compared with in-
hospital reperfusion treatments (104 vs 630 lives/10,000).98
Recommended are aspirin, b blockers, statins, renin–angioten-
sin system blockers and thienopyridines––a study of 5353 pa-
tients showing that treatment with all ﬁve drugs reduced 1-
year mortality by 74% compared with treatment with one or
none of them, with consistent effects in STEMI and NSTE-
MI.75 Evidence that statins and clopidogrel provides the great-
est independent pharmacological beneﬁt (ORs for death 0.85
(0.73–0.99) and 0.84 (0.72–0.99)) was provided by the GRACE
investigators in a nested case-control study of 5148 patients
with acute coronary syndromes,99 and two separate studies
have now reported the adverse consequences of failing to ad-
here to the treatment with these drugs during the ﬁrst year
after discharge.100,101 The message is clear that prescribing sec-
ondary prevention treatment according to guideline recom-
mendations and promoting adherence to treatment can
together produce further mortality reductions in patients with
myocardial infarction.
46 C. Knight, A.D. Timmis8. Implantable cardioverter-deﬁbrillators (ICDs)
Left ventricular ejection fraction (LVEF) after acute myocar-
dial infarction remains predictive of sudden death in the pri-
mary PCI era102 and is the key determinant of which patients
should be offered an ICD for primary prevention.103 However,
LVEF in the acute phase is an unreliable guide to LVEF at
3 months when signiﬁcant recovery of contractile function has
often occurred. But there is another reason for delaying deci-
sions about ICDs beyond the guideline-recommended 40 days.
Thus a recent randomised trial of ICD therapy in 898 patients
with LVEF 640%, recruited within 31 days of acute myocar-
dial infarction, showed no overall mortality reduction for the
patients who received an ICDbecause a high rate of non-sudden
death negated protection against sudden arrhythmic death pro-
vided by the ICD.104 A secondary analysis of DINAMIT has
now conﬁrmed a high risk of non-sudden death in patients
who receive ICDs early after myocardial infarction, while the
VALIANT investigators have reported that recurrent infarc-
tion or cardiac rupture are the common causes of death during
this period.105,106 Taken together, these ﬁndings explain why
ICDs fail to protect against death if implanted early after myo-
cardial infarction. Decisions should, therefore, be deferred, and
patients selected for ICD therapy according to themeasurement
of LVEF at 40 days.
9. Conclusion
The management of acute coronary syndromes continues to
evolve and improve. The challenge for cardiovascular
researchers is to maintain this momentum and to ensure that
the improvements in outcome seen in the developed world
have a global impact.
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